Skip to main content


Fig. 3 | Journal of Translational Medicine

Fig. 3

From: Crizotinib with or without an EGFR-TKI in treating EGFR-mutant NSCLC patients with acquired MET amplification after failure of EGFR-TKI therapy: a multicenter retrospective study

Fig. 3

Progression-free survival of patients with acquired MET amplification treated with crizotinib after developing EGFR-TKI resistance. a 14 patients received crizotinib treatment, mPFS was 6.6 months, 95% CI 3.884–9.316; b for patients receiving crizotinib plus EGFR-TKI vs. crizotinib monotherapy, 12.6 vs. 6.0 months (P = 0.315)

Back to article page